Skip to main content
françaisFR
European Commission logo print header

A sequential high throughput ion channel screening system for drug discovery in neurological and psychiatric disorders

Objectif

ION is a co-operative research proposal for the development of an innovative system capable of an efficient screening of candidate drugs on a wide set of targets (ion channels) involved in important neurological and psychiatric disorders, e.g. depression, Parkinson, epilepsy, migraine and pain. The proposers are a group of SMEs which includes technological companies and end users in the pharmaceutical sector. The RTD partners are required to provide the knowledge and the research capabilities to address the selection and optimization of the cellular targets and to validate the outcomes of the system in relation to the results of in vivo models of the pathologies of interest. However, an important contribution of the RTD partners will be to design a suite of innovative software agents for data analysis and experimental planning. The role of these agents is essential to achieve real high screening throughputs. The ION project will optimize the performance of a sequence of screening experiments instead of focusing on the execution of a single experiment. With respect to the current state of the art, the proposed development will introduce two important innovations. First, easy access to a large set of targets and to an efficient drug discovery process, exploiting a well designed and implemented library of starting molecular structures. Second, it will develop innovatively the analysis of the output and enable future experiments to be planned more effectively by introducing intelligent software agents interpreting the outcome of an experiment and planning the next experiment of a drug discovery screening sequence. The proposers estimate a large market in the EU, USA and Japan for their future products due to the expanding pharmaceutical research in the considered disorders which are still an unmet medical need. The proposing SMEs intend to present a common business plan in order to exploit the expected results worldwide.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

Data not available

Régime de financement

Cooperative - SMEs-Co-operative research contracts

Coordinateur

NEWRON PHARMACEUTICALS SPA
Contribution de l’UE
Aucune donnée
Adresse
Via Ariosto, 21
BRESSO (MI)
Italie

Voir sur la carte
Liens
Coût total
Aucune donnée

Participants (8)

Partager cette page

Télécharger

Dernière mise à jour: 7 Octobre 2010

Mon livret

Permalink: https://cordis.europa.eu/project/id/513190/fr

European Union, 2024